Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism - Wikidata - wikimedia - TriplyDB

Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism

Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism

http://www.wikidata.org/entity/Q33630525

about

Formononetin inhibits lipopolysaccharide-induced release of high mobility group box 1 by upregulating SIRT1 in a PPARδ-dependent manner.Polyphenols isolated from virgin coconut oil attenuate cadmium-induced dyslipidemia and oxidative stress due to their antioxidant properties and potential benefits on cardiovascular risk ratios in rats.Hypolipidemic effect of Fragarianilgerrensis Schlecht. medicine compound on hyperlipidemic rats

P2860

Q47220236-82EDA3CB-1418-4C53-9725-CDFFEEC0DF8D Q49529653-27C1E64E-7CC3-4622-B8EE-8B55D6F3E9D8 Q58718830-212BFE45-4C20-47F7-A50C-27C5E8C779CC

P2860

Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism

http://www.wikidata.org/entity/Q33630525

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism

@ast

Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism

@en

type

label

Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism

@ast

Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism

@en

prefLabel

Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism

@ast

Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism

@en

P1433

Q33630525-76B09575-DE6B-40B6-9122-B1834EF411D1

P1476

Q33630525-01B16C66-BD92-4F75-BE4E-DB55F14D398E

P2093

Q33630525-047D0A19-AC43-4251-A9B3-293372FC5B1F

Q33630525-363931F1-274C-4C35-8CFE-B7BBBCD4B47E

Q33630525-9F58DF54-0B8F-4118-91EB-9B30B6834F66

Q33630525-C961DFBB-42B9-4C7F-B06A-DCA3E8FC28D0

Q33630525-D25A6B68-223B-4B6C-86E4-4A8A8E91FD6D

Q33630525-E58E553A-A992-4F0F-9509-028ABFE28BCB

P2860

Q33630525-0620D5A3-7A42-4812-9645-2B604144CBF4

Q33630525-1279B2A4-D074-4FEC-95DC-7D85D3B1D859

Q33630525-1464BCFA-CBF5-4D30-8C25-5532B5343BDD

Q33630525-161105CC-D8B8-48BC-8D41-1EF8A722591B

Q33630525-1EF197A5-0214-4168-A978-40E1483DDC66

Q33630525-210ED29C-D1CC-486C-B2C9-F0BEFE7EA2DA

Q33630525-28E192EB-AE42-4960-BC5A-91B1F15DCEFC

Q33630525-29174FE7-B749-437B-835F-9DC9FC51585B

Q33630525-2DFFC94E-00CA-4C67-A8F7-0FBBD176D9E3

Q33630525-35C22957-BCD4-41F6-AECC-5951FF73B8A2

P2888

Q33630525-47F3B981-D57B-4FA1-88EF-180CD9E21D4F

P304

Q33630525-EB3F07C1-30F3-4FC7-83EE-71C30FDE7E59

P31

Q33630525-0003D695-5F19-496C-85D6-66A4A3C4F5DC

P356

Q33630525-15434119-0DFE-4A6A-8318-1F02CA090D05

P433

Q33630525-73B724AA-BBF0-4971-81A4-7AD913BDB3BB

P478

Q33630525-006DB848-22E2-419E-AB6A-F94B969DA511

P50

Q33630525-22A636A3-6801-4899-8CAC-34FC2A65585B

Q33630525-7D59878C-E136-4EEE-A717-3D89B3B57706

P577

Q33630525-2E5DE581-210F-4872-B2A6-580ABB521897

P6179

Q33630525-B0F11ADA-8A77-4022-A6E4-CC6F1BED098B

P698

Q33630525-2DF612FC-B9F4-466F-8EDA-8B70E38952EE

P921

Q33630525-15C94D3B-EEF6-4177-BFF6-109B65F8AF1B

P932

Q33630525-C276C545-0C80-44DB-BA8C-2F048D2C58C3

P356

S12944-017-0472-Z

P1433

Lipids in Health and Disease

P1476

Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism

@en

P2093

Hong Shen

http://www.w3.org/2001/XMLSchema#string

Meng-Jie Zhao

http://www.w3.org/2001/XMLSchema#string

Pei Xu

http://www.w3.org/2001/XMLSchema#string

Shan-Shan Wang

http://www.w3.org/2001/XMLSchema#string

Yao Jiang

http://www.w3.org/2001/XMLSchema#string

Ying Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

Traditional chinese medicine in treatment of metabolic syndrome

Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors

Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes

Isoflavones and PPAR Signaling: A Critical Target in Cardiovascular, Metastatic, and Metabolic Disease

Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Statin safety: an overview and assessment of the data--2005.

P2888

s12944-017-0472-z

P304

85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12944-017-0472-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084956336

http://www.w3.org/2001/XMLSchema#string

P698

28464894

http://www.w3.org/2001/XMLSchema#string

P921

P932

5414347

http://www.w3.org/2001/XMLSchema#string